News
IOVA
11.54
-1.45%
-0.17
AHN Cancer Institute To Offer Groundbreaking Treatment For Metastatic Melanoma; The One-Time Treatment, Made By Iovance Biotherapeutics, Is The First FDA-Approved T-Cell Therapy For Solid Tumors
AHN Cancer Institute is first in western Pennsylvania to offer a first-of-its-kind cellular therapy to treat metastatic melanoma. Amtagvi is the first FDA-approved T-cell therapy for solid tumors. The therapy uses the patient's immune cells to fight the cancer. The American Cancer Society estimates 100,000 new melanomas will be diagnosed in 2024.
Benzinga · 3d ago
Weekly Report: what happened at IOVA last week (0415-0419)?
Weekly Report · 3d ago
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Iovance Biotherapeutics, Inc. Approved the grant of inducement stock options covering an aggregate of 79,310 shares of Iovance’s common stock to thirty-seven new, non-executive employees on April 18, 2024. The company is a biotechnology company focused on cancer treatments.
Barchart · 6d ago
Lyell Immunopharma: Testing The T-Cell Thesis With 2 Upcoming Data Catalysts
Seeking Alpha · 04/16 22:25
Iovance Biotherapeutics Enters Oversold Territory (IOVA)
NASDAQ · 04/15 20:46
Weekly Report: what happened at IOVA last week (0408-0412)?
Weekly Report · 04/15 10:17
Exelixis slips as Barclays downgrades on lack of catalysts
Barclays downgrades cancer drugmaker Exelixis on lack of catalysts. Lead asset cabozantinib faces a patent cliff, analyst says. Barclays sees better upside potential in other companies with similar pipelines. Exelxis shares traded lower on Thursday.
Seeking Alpha · 04/11 14:10
Iovance Biotherapeutics: Riding The Favorable Moment Could Bring Excellent Results
Seeking Alpha · 04/09 10:05
Iovance (IOVA) Stock Surges More Than 60% YTD: Here's Why
NASDAQ · 04/08 17:51
Weekly Report: what happened at IOVA last week (0401-0405)?
Weekly Report · 04/08 10:20
Sum Up The Parts: VB Could Be Worth $245
NASDAQ · 04/05 10:53
Weekly Report: what happened at IOVA last week (0325-0329)?
Weekly Report · 04/01 10:19
Iovance Board Changes: McPeak Retires, Vogt Nominated
Merrill A. McPeak, a key figure on the Board of Directors for Iovance Biotherapeutics, Inc., will not seek re-election. His departure is amicable, with no conflicts cited regarding company operations or policies. Frederick Vogt, the interim CEO and president of IOVance, will fill the vacancy.
TipRanks · 03/29 21:12
Iovance Biotherapeutics (IOVA) Down 6.9% Since Last Earnings Report: Can It Rebound?
NASDAQ · 03/29 15:30
May 10th Options Now Available For Iovance Biotherapeutics (IOVA)
NASDAQ · 03/28 15:19
Iovance Biotherapeutics: Initial Amtagvi Launch In Focus
Iovance Biotherapeutics' Amtagvi was recently approved in the US for the treatment of advanced melanoma patients. Initial numbers from the launch of the company's product show high demand for the product. Iovance's tumor-infiltrating lymphocyte product, amtagvi, was approved in February. The company has a cash position of $485.2M and is rated a hold.
Seeking Alpha · 03/25 18:29
Weekly Report: what happened at IOVA last week (0318-0322)?
Weekly Report · 03/25 10:21
Rise Of The Rest, Look Past Mega Caps, And Invest Elsewhere
David Lerner: The rate of rise for big-cap tech stocks is slowing down or losing altitude. He says it may not be the best time to invest in them. The economy is growing, inflation is under control, and the Fed is committed to cutting rates. Look past the Mega Cap Tech to Invest and invest in other sectors.
Seeking Alpha · 03/25 03:25
U.S.-China Decoupling Poses Supply-Chain Risks for Drug Companies -- Heard on the Street
Congress is considering a bill to blacklist certain Chinese biotech companies. U.S. Companies have outsourced contract manufacturing and research to Chinese companies. The bill could have unintended consequences for companies that rely on those companies for drug development. Congress is considering the legislation to protect national-security concerns.
The Wall Street Journal · 03/23 13:00
BRIEF-Iovance Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Reuters · 03/22 21:31
More
Webull provides a variety of real-time IOVA stock news. You can receive the latest news about Iovance Biotherp through multiple platforms. This information may help you make smarter investment decisions.
About IOVA
Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company develops and delivers tumor infiltrating lymphocyte (TIL), therapies for patients with solid tumor cancers. Its lead product candidate, Amtagvi (lifileucel), is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. The Company also marketing Proleukin (aldesleukin), aninterleukin-2, or IL-2, product used in the Amtagvi treatment regimen. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings for solid tumor cancers. Amtagvi and Proleukin are part of a treatment regimen that also includes lymphodepletion. The Company is also developing next generation therapies using TIL, such as genetically modified TIL cell therapy.